Aligos Therapeutics Secures $105M in Private Placement

Aligos Therapeutics ( (ALGS) ) has provided an announcement.

On February 11, 2025, Aligos Therapeutics entered into a Securities Purchase Agreement with investors for a private placement, expected to result in approximately $105 million in gross proceeds. This funding is anticipated to support the advancement of their ALG-000184 into a Phase 2 clinical study and extend the company’s cash runway into the second half of 2026. The private placement, led by a life sciences investment firm, involves the sale of common stock and warrants and is expected to close on February 13, 2025. This financial boost is a strategic move to solidify Aligos’s position in the biotechnology industry focused on liver and viral diseases, providing potential long-term benefits for stakeholders.

More about Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver and viral diseases, including chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, and coronaviruses.

YTD Price Performance: -34.66%

Average Trading Volume: 416,981

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $99.38M

Learn more about ALGS stock on TipRanks’ Stock Analysis page.